Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Placebo
- drug: Elenbecestat
Eligibility
Inclusion Criteria:
Core Study
- Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia
including
1. Mini Mental State Examination score equal to or greater than 24
2. Clinical Dementia Rating (CDR) global score of 0.5
3. CDR Memory Box score of 0.5 or greater
- Impaired episodic memory confirmed by a list learning task
- Positive biomarker for brain amyloid pathology as indicated by either amyloid positron
emission tomography or cerebrospinal fluid AD assessment or both
Extension Phase
• Participants who complete the Core Study
Exclusion Criteria:
Core Study
- Females who are breastfeeding or pregnant at Screening or Baseline. Females of
child-bearing potential must use a highly effective method of contraception throughout
the entire study period and for 28 days after study drug discontinuation
- Any condition that may be contributing to cognitive impairment above and beyond that
caused by the participant's AD
- Participants with a history of seizures within 5 years of Screening
- History of transient ischemic attacks or stroke within 12 months of Screening
- Psychiatric diagnosis or symptoms (example, hallucinations, major depression,
delusions etc.)
- Suicidal ideation or any suicidal behavior within 6 months before Screening or has
been hospitalized or treated for suicidal behavior in the past 5 years
- Have any contraindications to magnetic resonance imaging (MRI) scanning or
1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
2. Exhibit other significant pathological findings on brain MRI.
- Participants who have a history of moderate to severe hepatic impairment (example,
Child-Pugh Class B or C)
- Results of laboratory tests conducted during Screening that are outside the following
limits:
1. Absolute lymphocyte count below the lower limit of normal (LLN)
2. Thyroid stimulating hormone above normal range
3. Abnormally low Vitamin B12 levels
- Participants at increased risk of infection
- Have received any live vaccine/live attenuated vaccine in the 3 months before
randomization
- Any chronic inflammatory disease that is not adequately controlled or that requires
systemic immunosuppressive or immunomodulatory therapy
- Any other clinically significant abnormalities
- Severe visual or hearing impairment
- A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction
[QTcF] greater than 450 milliseconds [ms])
- Malignant neoplasms within 5 years of Screening
- Known or suspected history of drug or alcohol abuse
- Taking prohibited medications, which must be reviewed with the Investigator
- Have participated in a recent clinical study
Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
Ages Eligible for Study
50 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Placebo
- drug: Elenbecestat
Eligibility
Inclusion Criteria:
Core Study
- Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia
including
1. Mini Mental State Examination score equal to or greater than 24
2. Clinical Dementia Rating (CDR) global score of 0.5
3. CDR Memory Box score of 0.5 or greater
- Impaired episodic memory confirmed by a list learning task
- Positive biomarker for brain amyloid pathology as indicated by either amyloid positron
emission tomography or cerebrospinal fluid AD assessment or both
Extension Phase
• Participants who complete the Core Study
Exclusion Criteria:
Core Study
- Females who are breastfeeding or pregnant at Screening or Baseline. Females of
child-bearing potential must use a highly effective method of contraception throughout
the entire study period and for 28 days after study drug discontinuation
- Any condition that may be contributing to cognitive impairment above and beyond that
caused by the participant's AD
- Participants with a history of seizures within 5 years of Screening
- History of transient ischemic attacks or stroke within 12 months of Screening
- Psychiatric diagnosis or symptoms (example, hallucinations, major depression,
delusions etc.)
- Suicidal ideation or any suicidal behavior within 6 months before Screening or has
been hospitalized or treated for suicidal behavior in the past 5 years
- Have any contraindications to magnetic resonance imaging (MRI) scanning or
1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
2. Exhibit other significant pathological findings on brain MRI.
- Participants who have a history of moderate to severe hepatic impairment (example,
Child-Pugh Class B or C)
- Results of laboratory tests conducted during Screening that are outside the following
limits:
1. Absolute lymphocyte count below the lower limit of normal (LLN)
2. Thyroid stimulating hormone above normal range
3. Abnormally low Vitamin B12 levels
- Participants at increased risk of infection
- Have received any live vaccine/live attenuated vaccine in the 3 months before
randomization
- Any chronic inflammatory disease that is not adequately controlled or that requires
systemic immunosuppressive or immunomodulatory therapy
- Any other clinically significant abnormalities
- Severe visual or hearing impairment
- A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction
[QTcF] greater than 450 milliseconds [ms])
- Malignant neoplasms within 5 years of Screening
- Known or suspected history of drug or alcohol abuse
- Taking prohibited medications, which must be reviewed with the Investigator
- Have participated in a recent clinical study
Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
Ages Eligible for Study
50 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Placebo
- drug: Elenbecestat
Eligibility
Inclusion Criteria:
Core Study
- Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia
including
1. Mini Mental State Examination score equal to or greater than 24
2. Clinical Dementia Rating (CDR) global score of 0.5
3. CDR Memory Box score of 0.5 or greater
- Impaired episodic memory confirmed by a list learning task
- Positive biomarker for brain amyloid pathology as indicated by either amyloid positron
emission tomography or cerebrospinal fluid AD assessment or both
Extension Phase
• Participants who complete the Core Study
Exclusion Criteria:
Core Study
- Females who are breastfeeding or pregnant at Screening or Baseline. Females of
child-bearing potential must use a highly effective method of contraception throughout
the entire study period and for 28 days after study drug discontinuation
- Any condition that may be contributing to cognitive impairment above and beyond that
caused by the participant's AD
- Participants with a history of seizures within 5 years of Screening
- History of transient ischemic attacks or stroke within 12 months of Screening
- Psychiatric diagnosis or symptoms (example, hallucinations, major depression,
delusions etc.)
- Suicidal ideation or any suicidal behavior within 6 months before Screening or has
been hospitalized or treated for suicidal behavior in the past 5 years
- Have any contraindications to magnetic resonance imaging (MRI) scanning or
1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
2. Exhibit other significant pathological findings on brain MRI.
- Participants who have a history of moderate to severe hepatic impairment (example,
Child-Pugh Class B or C)
- Results of laboratory tests conducted during Screening that are outside the following
limits:
1. Absolute lymphocyte count below the lower limit of normal (LLN)
2. Thyroid stimulating hormone above normal range
3. Abnormally low Vitamin B12 levels
- Participants at increased risk of infection
- Have received any live vaccine/live attenuated vaccine in the 3 months before
randomization
- Any chronic inflammatory disease that is not adequately controlled or that requires
systemic immunosuppressive or immunomodulatory therapy
- Any other clinically significant abnormalities
- Severe visual or hearing impairment
- A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction
[QTcF] greater than 450 milliseconds [ms])
- Malignant neoplasms within 5 years of Screening
- Known or suspected history of drug or alcohol abuse
- Taking prohibited medications, which must be reviewed with the Investigator
- Have participated in a recent clinical study
Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
Ages Eligible for Study
50 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Placebo
- drug: Elenbecestat
Eligibility
Inclusion Criteria:
Core Study
- Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia
including
1. Mini Mental State Examination score equal to or greater than 24
2. Clinical Dementia Rating (CDR) global score of 0.5
3. CDR Memory Box score of 0.5 or greater
- Impaired episodic memory confirmed by a list learning task
- Positive biomarker for brain amyloid pathology as indicated by either amyloid positron
emission tomography or cerebrospinal fluid AD assessment or both
Extension Phase
• Participants who complete the Core Study
Exclusion Criteria:
Core Study
- Females who are breastfeeding or pregnant at Screening or Baseline. Females of
child-bearing potential must use a highly effective method of contraception throughout
the entire study period and for 28 days after study drug discontinuation
- Any condition that may be contributing to cognitive impairment above and beyond that
caused by the participant's AD
- Participants with a history of seizures within 5 years of Screening
- History of transient ischemic attacks or stroke within 12 months of Screening
- Psychiatric diagnosis or symptoms (example, hallucinations, major depression,
delusions etc.)
- Suicidal ideation or any suicidal behavior within 6 months before Screening or has
been hospitalized or treated for suicidal behavior in the past 5 years
- Have any contraindications to magnetic resonance imaging (MRI) scanning or
1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
2. Exhibit other significant pathological findings on brain MRI.
- Participants who have a history of moderate to severe hepatic impairment (example,
Child-Pugh Class B or C)
- Results of laboratory tests conducted during Screening that are outside the following
limits:
1. Absolute lymphocyte count below the lower limit of normal (LLN)
2. Thyroid stimulating hormone above normal range
3. Abnormally low Vitamin B12 levels
- Participants at increased risk of infection
- Have received any live vaccine/live attenuated vaccine in the 3 months before
randomization
- Any chronic inflammatory disease that is not adequately controlled or that requires
systemic immunosuppressive or immunomodulatory therapy
- Any other clinically significant abnormalities
- Severe visual or hearing impairment
- A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction
[QTcF] greater than 450 milliseconds [ms])
- Malignant neoplasms within 5 years of Screening
- Known or suspected history of drug or alcohol abuse
- Taking prohibited medications, which must be reviewed with the Investigator
- Have participated in a recent clinical study
Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
Ages Eligible for Study
50 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Placebo
- drug: Elenbecestat
Eligibility
Inclusion Criteria:
Core Study
- Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia
including
1. Mini Mental State Examination score equal to or greater than 24
2. Clinical Dementia Rating (CDR) global score of 0.5
3. CDR Memory Box score of 0.5 or greater
- Impaired episodic memory confirmed by a list learning task
- Positive biomarker for brain amyloid pathology as indicated by either amyloid positron
emission tomography or cerebrospinal fluid AD assessment or both
Extension Phase
• Participants who complete the Core Study
Exclusion Criteria:
Core Study
- Females who are breastfeeding or pregnant at Screening or Baseline. Females of
child-bearing potential must use a highly effective method of contraception throughout
the entire study period and for 28 days after study drug discontinuation
- Any condition that may be contributing to cognitive impairment above and beyond that
caused by the participant's AD
- Participants with a history of seizures within 5 years of Screening
- History of transient ischemic attacks or stroke within 12 months of Screening
- Psychiatric diagnosis or symptoms (example, hallucinations, major depression,
delusions etc.)
- Suicidal ideation or any suicidal behavior within 6 months before Screening or has
been hospitalized or treated for suicidal behavior in the past 5 years
- Have any contraindications to magnetic resonance imaging (MRI) scanning or
1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
2. Exhibit other significant pathological findings on brain MRI.
- Participants who have a history of moderate to severe hepatic impairment (example,
Child-Pugh Class B or C)
- Results of laboratory tests conducted during Screening that are outside the following
limits:
1. Absolute lymphocyte count below the lower limit of normal (LLN)
2. Thyroid stimulating hormone above normal range
3. Abnormally low Vitamin B12 levels
- Participants at increased risk of infection
- Have received any live vaccine/live attenuated vaccine in the 3 months before
randomization
- Any chronic inflammatory disease that is not adequately controlled or that requires
systemic immunosuppressive or immunomodulatory therapy
- Any other clinically significant abnormalities
- Severe visual or hearing impairment
- A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction
[QTcF] greater than 450 milliseconds [ms])
- Malignant neoplasms within 5 years of Screening
- Known or suspected history of drug or alcohol abuse
- Taking prohibited medications, which must be reviewed with the Investigator
- Have participated in a recent clinical study
Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
Ages Eligible for Study
50 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Placebo
- drug: Elenbecestat
Eligibility
Inclusion Criteria:
Core Study
- Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia
including
1. Mini Mental State Examination score equal to or greater than 24
2. Clinical Dementia Rating (CDR) global score of 0.5
3. CDR Memory Box score of 0.5 or greater
- Impaired episodic memory confirmed by a list learning task
- Positive biomarker for brain amyloid pathology as indicated by either amyloid positron
emission tomography or cerebrospinal fluid AD assessment or both
Extension Phase
• Participants who complete the Core Study
Exclusion Criteria:
Core Study
- Females who are breastfeeding or pregnant at Screening or Baseline. Females of
child-bearing potential must use a highly effective method of contraception throughout
the entire study period and for 28 days after study drug discontinuation
- Any condition that may be contributing to cognitive impairment above and beyond that
caused by the participant's AD
- Participants with a history of seizures within 5 years of Screening
- History of transient ischemic attacks or stroke within 12 months of Screening
- Psychiatric diagnosis or symptoms (example, hallucinations, major depression,
delusions etc.)
- Suicidal ideation or any suicidal behavior within 6 months before Screening or has
been hospitalized or treated for suicidal behavior in the past 5 years
- Have any contraindications to magnetic resonance imaging (MRI) scanning or
1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
2. Exhibit other significant pathological findings on brain MRI.
- Participants who have a history of moderate to severe hepatic impairment (example,
Child-Pugh Class B or C)
- Results of laboratory tests conducted during Screening that are outside the following
limits:
1. Absolute lymphocyte count below the lower limit of normal (LLN)
2. Thyroid stimulating hormone above normal range
3. Abnormally low Vitamin B12 levels
- Participants at increased risk of infection
- Have received any live vaccine/live attenuated vaccine in the 3 months before
randomization
- Any chronic inflammatory disease that is not adequately controlled or that requires
systemic immunosuppressive or immunomodulatory therapy
- Any other clinically significant abnormalities
- Severe visual or hearing impairment
- A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction
[QTcF] greater than 450 milliseconds [ms])
- Malignant neoplasms within 5 years of Screening
- Known or suspected history of drug or alcohol abuse
- Taking prohibited medications, which must be reviewed with the Investigator
- Have participated in a recent clinical study
Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
Ages Eligible for Study
50 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting